(Health-NewsWire.Net, July 29, 2017 ) Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP) . It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis.
Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders and Women's Health which include indications Rheumatoid Arthritis, Type 1 Diabetes (Juvenile Diabetes) , Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Cervical Intraepithelial Neoplasia (CIN) , High-Grade Glioma, Human Papillomavirus Infections, Lymphocytopenia, Multiple Sclerosis, Non-Small Cell Lung Cancer, Sepsis, Sicca Syndrome (Sjogren) , Solid Tumor, Transplant Rejection and Ulcerative Colitis.
The latest report Interleukin 7 Receptor Subunit Alpha - Pipeline Review, H2 2017, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/survival-motor-neuron-protein-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics Request a sample copy at http://www.reportsweb.com/inquiry&RW0001884181/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles Genexine Inc GlaxoSmithKline Plc OSE Immunotherapeutics Pfizer Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001884181/discount
List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Genexine Inc, H2 2017 Pipeline by GlaxoSmithKline Plc, H2 2017 Pipeline by OSE Immunotherapeutics, H2 2017 Pipeline by Pfizer Inc, H2 2017 Dormant Projects, H2 2017 Discontinued Products, H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001884181/buy/3500
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|